Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
…, A Zeaiter, K Zaman, V Boni, J Arrondeau… - The lancet …, 2020 - thelancet.com
Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription…
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription…
[HTML][HTML] Pericardial effusion under nivolumab: case-reports and review of the literature
A Saade, A Mansuet-Lupo, J Arrondeau… - … for immunotherapy of …, 2019 - Springer
Background Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint
inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer …
inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer …
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
…, N Pécuchet, M Alifano, H Ouakrim, J Arrondeau… - Clinical Cancer …, 2018 - AACR
Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1 (PD-1)
exhibit impressive clinical results in non–small cell lung cancer, underlining the strong …
exhibit impressive clinical results in non–small cell lung cancer, underlining the strong …
[HTML][HTML] Development of anti-cancer drugs
J Arrondeau, HK Gan, ARA Razak… - Discovery …, 2010 - discoverymedicine.com
Every new anti-cancer drug or drug combination is evaluated for safety and efficacy before
being approved. Clinical development of cytotoxic anticancer drugs classically follows three …
being approved. Clinical development of cytotoxic anticancer drugs classically follows three …
[HTML][HTML] The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
D Damotte, S Warren, J Arrondeau… - Journal of Translational …, 2019 - Springer
Background The 18-gene tumor inflammation signature (TIS) is a clinical research assay
that enriches for clinical benefit to immune checkpoint blockade. We evaluated its ability to …
that enriches for clinical benefit to immune checkpoint blockade. We evaluated its ability to …
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
…, P Boudou-Rouquette, J Chanal, J Arrondeau… - Investigational new …, 2017 - Springer
Little is known on factors predicting toxicity of anti-PD1 checkpoint inhibitors. Sarcopenic
obesity is associated with increased acute toxicity of cytotoxic agents and targeted therapies. …
obesity is associated with increased acute toxicity of cytotoxic agents and targeted therapies. …
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
J Arrondeau, O Mir, P Boudou-Rouquette… - Investigational new …, 2012 - Springer
Background Intra-patient variability in sorafenib pharmacokinetics has been poorly investigated
to date. We hypothesized that sorafenib clearance could decrease over time, as seen …
to date. We hypothesized that sorafenib clearance could decrease over time, as seen …
[HTML][HTML] Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study
…, C Tlemsani, N Khoudour, J Arrondeau… - Cancers, 2020 - mdpi.com
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1)
therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD…
therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD…
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib
C Tlemsani, O Huillard, J Arrondeau… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: UDP-glucuronosyltransferases (UGTs) are a multigenic family of enzymes
responsible for the glucuronidation reaction. Many therapeutic classes of drugs used in solid …
responsible for the glucuronidation reaction. Many therapeutic classes of drugs used in solid …
Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade
…, C Bantsimba-Malanda, J Arrondeau… - American Journal of …, 2018 - atsjournals.org
Rationale: Patients with chronic obstructive pulmonary disease (COPD) have a higher
prevalence of lung cancer. The chronic inflammation associated with COPD probably promotes …
prevalence of lung cancer. The chronic inflammation associated with COPD probably promotes …